Syntara - SNT(ASX) News & Expert Insights from Stockhead

Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Syntara.

Weekly small cap wrap: Who entertained a big purchase?

August 16, 2019December 18, 2023 | Reuben Adams

Health & Biotech

Health: Pharmaxis tumbles way into the red as fortunes fluctuate on handballed drug

August 15, 2019December 18, 2023 | Daniel Paproth

Health & Biotech

Dr Boreham’s Crucible: Pharmaxis shareholders breathe easy – the FDA loves you

July 22, 2019December 18, 2023 | Tim Boreham

Health & Biotech

Health: Pharmaxis on verge of $14.3m payout after FDA close call on Bronchitol

May 9, 2019December 18, 2023 | Daniel Paproth

Health & Biotech

Fatty liver disease drug maker Pharmaxis adds pancreatic cancer to lineup

February 22, 2019December 18, 2023 | Daniel Paproth

Health & Biotech

Pharmaxis just posted a $12.6m half-year loss, but it’s not as bad as it looks

February 15, 2019December 18, 2023 | Daniel Paproth

Health & Biotech

Resonance Health just went from wallflower to overnight wonder: here’s why

January 16, 2019December 18, 2023 | Rachel Williamson

Health & Biotech

Pharmaxis says Big Pharma can’t wait to get a cut of its drugs

November 15, 2018December 18, 2023 | Daniel Paproth

Health & Biotech

Pharmaxis gets another fatty liver drug through clinical trials; shares gain

October 11, 2018December 18, 2023 | Rachel Williamson

Health & Biotech

Drug developer Pharmaxis turns loss into $6m profit

August 17, 2018December 18, 2023 | Daniel Paproth

Health & Biotech

What biotech success looks like: a $15m payout when someone else trials your drug

January 11, 2018December 18, 2023 | Rachel Williamson

Syntara
(ASX:SNT)

SNT Share Price and Trading History

RELATED STOCKHEAD STORIES

Weekly small cap wrap: Who entertained a big purchase?

Health: Pharmaxis tumbles way into the red as fortunes fluctuate on handballed drug

Dr Boreham’s Crucible: Pharmaxis shareholders breathe easy – the FDA loves you

Health: Pharmaxis on verge of $14.3m payout after FDA close call on Bronchitol

Fatty liver disease drug maker Pharmaxis adds pancreatic cancer to lineup

Pharmaxis just posted a $12.6m half-year loss, but it’s not as bad as it looks

Resonance Health just went from wallflower to overnight wonder: here’s why

Pharmaxis says Big Pharma can’t wait to get a cut of its drugs

Pharmaxis gets another fatty liver drug through clinical trials; shares gain

Drug developer Pharmaxis turns loss into $6m profit

What biotech success looks like: a $15m payout when someone else trials your drug

SNT Share Price and Trading History

SNT Share Price and Trading History

RELATED STOCKHEAD STORIES

SNT Share Price and Trading History

Don't be the last to know

Editor's Picks

Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial

Graphite is on the canvas, but as prices rise Aussie producers will be cost competitive

IoT and AI reshaping energy and utilities, and these ASX players are making their moves

The childcare sector is growing up fast, and ASX companies like Finexia are benefitting

Kristie Batten: VHM just months from FID on groundbreaking Victorian rare earths mine

Get the latest Stockhead news delivered free to your inbox

I want the news: